Archive For The “Israeli Medicine” Category
We originally reported on this cancer cure story a few weeks back. Subsequently, a lot of red flags started appearing about the AEBi (Accelerated Evolution Biotechnologies, Ltd), including:
- The cancer cure would be available from day one and the subject will be completely cancer free within a year.
- That AEBi offered no evidence for its claim, only that they did not have enough funding to produce peer-reviewed publications.
- laims to be able to cure all forms of cancer.
- A notable cancer research scientist reported in a Forbes that the AEBi claimed to attack cancer cells three at a time, which is strange since cancer cells themselves can’t do that.
The following excerpts were originally reported by NoCamels.com
The new development was picked up by numerous media publications in Israel and across the world. Meanwhile, AEBi offered no evidence of its findings and claimed not to have the funds to publish any in peer-reviewed scientific journals.
But the company says its developed treatment, MuTaTo (multi-target toxin), is a new, multi-pronged attack on cancer cells using peptides that showed “consistent and repeatable” results in the “first exploratory mice experiment, which inhibited human cancer cell growth and had no effect at all on healthy mice cells, in addition to several in-vitro trials,” the Jerusalem Post reported.
Dr. Victoria Forster, a cancer research scientist and postdoctoral fellow at The Hospital for Sick Children (SickKids) in Toronto, Canada, wrote in a Forbes piece that the first “red flag” for her was a claim by AEBi’s CEO Dr. Ilan Morad on what the treatment could achieve.
“Instead of attacking receptors one at a time, we attack receptors three at a time – not even cancer can mutate three receptors at the same time,” Morad had told the Jerusalem Post.
“This is categorically untrue,” wrote Forster. “Cancers can have anywhere from one to tens of thousands of DNA mutations in their genomes, many of these being the ‘receptors’ Morad vaguely refers to. A key principle of using multiple chemotherapy agents at once is to go after cancer cells by several different routes to reduce the chance that they will become resistant. Still, many cancers do become resistant to these treatment protocols, so Morad’s logic here is extremely shaky.”
Furthermore, the Israeli company’s claim that its treatment will work for all types of cancers is also a “huge red flag,” she said.
“There are broadly over 200 different types of cancer and within those, multiple other subtypes. For there to be one, universal ‘cancer cure’ that overcomes all of these differences is highly unlikely,” Forster charged.
An Australian cancer research scientist went a step further, accusing the company of “selling unicorns” and calling for it to be hung out “to dry for making such cruel and misleading claims.”
In reference to popular culture, cancer biologist Dr. Darren Saunders said
Dr. J. Leonard Lichtenfeld, the deputy chief medical officer for the national office of the American Cancer Society, wrote in a blog post titled “A Cure For Cancer? Not So Fast” that while the Israeli scientists “worked with an interesting approach to interfering with the ability of cancer cells to function,” they provided very limited information that has “not been published in the scientific literature where it would be subject to review, support and/or criticism from knowledgeable peers.”
He further noted that AEBi’s initial experiment on mice in clinical trials “is not a well-established program of experiments which could better define how this works—and may not work—as it moves from the laboratory bench to the clinic.”
“The gap from a successful mouse experiment to effective, beneficial application of exciting laboratory concepts to helping cancer patients at the bedside is, in fact, a long and treacherous journey, filled with unforeseen and unanticipated obstacles,” Lichtenfeld wrote, pouring cold water on the claim that the treatment would be available in a year.
Who would have thunk it. Israeli farmers lining up to grow pot. You are not living in some alternative universe. That’s what’s going on right now in Israel. And the government is supporting the initiative which it expects to generate $1billion in exports per year, and that’s even with a cannabis-hostile Trump administration.
The following text was originally reported in NoCamels.com.
According to Israeli government research, medical cannabis exports is set to bring in an estimated $1 billion in revenue per year. Since the government announced the reforms two years ago, some 400 Israeli farmers applied for permits to grow cannabis, the Israeli Health Ministry said last year, with another 242 receiving preliminary approval. The ministry also said it received some 200 applications for cannabis nurseries seeking to distribute cannabis plants, 95 requests to set up cannabis pharmacies, 60 applications for processing facilities, and 44 requests to set up stores selling cannabis products.
The medical cannabis exports law hit a snag last year when Prime Minister Benjamin Netanyahu, much to the dismay of the local industry, froze export plans amid political wrangling and opposition by the Ministry of Public Security headed by Gilad Erdan which said it was afraid plants grown for exports would spill over into the recreational market, and demanded some NIS 200 million to its budget to help secure facilities. A reported conversation with US President Donald Trump, whose administration is taking a hard line against cannabis including its medical use, was also said to be the cause of the sudden export freeze.
The revised law provides a budget for police to monitor, track and control the production and delivery of cannabis for export, and prevent said spill over. Recreational use of cannabis in Israel is still not legal but licensed medical cannabis consumption for vetted physical and mental health issues has been allowed for a decade.
The law also specifies that any foreign investment of more than five percent in an Israeli cannabis company will require regulatory approval.
We already have smartphone apps to check heart rates, blood pressure, and other vital signs. So why not a device, a very nonintrusive device that can detect diseases without having to undergo intrusive, stressful, and expensive medical testing? That’s exactly what Israeli researcher Hossam Haick has created.
The remainder the this text was originally published by NoCamels.com
Israeli Professor Hossam Haick of the Wolfson Faculty of Chemical Engineering at the Technion – Israel Institute of Technology was awarded the European Commission Innovation Prize last week for his invention of the SNIFFPHONE, a device that uses nanotechnology sensors to analyze particles on the breath and is able to pinpoint to exact diseases, like certain kinds of cancer, pulmonary and even the early stages of neurodegenerative diseases.
Haick was awarded the prize last week in Lisbon, Portugal at the annual European Forum of Electronic Components and Systems (
The SNIFFPHONE includes the NaNose, developed in 2014 by Haick and Professor Nir Peled of Tel Aviv University’s Sackler Faculty of Medicine. It is a microchip incorporated into a the breathalyzer-like device, capable of diagnosing various diseases. The device uses the presence of specific volatile organic compounds, which are unique fingerprints for various forms of diseases.
“We look for what are called volatile organic compounds, or biomarkers, on the breath. These biomarkers are chemical compounds that are imitated from the source of the disease and, as a result, are diffused within the bloodstream. Of course, the bloodstream is in contact with the skin and the lungs, which is why our test is able to detect them,” Haick told NoCamels in 2015.
In a 2017 study led by Haick and which involved 1404 participants from five countries, the NaNose was able to differentiate between malignant and benign tumors, as well as their source, with almost 90 percent accuracy.
The SNIFFPHONE and NaNose are among a long list of achievements for the award-winning scientist. He holds dozens of patents and made it into a number of notable lists, including the “World’s 35 leading young scientists” by the MIT Technology Review for his research in non-invasive disease detection methods, and a list of 100 most influential inventors by several international agencies between 2015-2018.
The European Commission previously awarded him $6.8 million for further development of the NaNose.
He’s also won an array of prizes and medals, including Knight in Order of the Academic Palms by the French Government, the Humboldt Award, the Bill and Melinda Gates Prize and the Herschel Ritz Innovation Award.
He currently serves as faculty and F.M.W. Academic Chair in the Department of Chemical Engineering at Technion and serves as a consultant to several commercial companies that spun out of his laboratories at the prestigious university.
His latest work, alongside Technion postdoctoral researcher Weiwei Wu, involves wearable health devices that include electrodes and sensors applied onto nylon textiles and permeable skin-mimicking bandages that constantly monitor breath rate, skin odor and chemical biomarkers (saliva, sweat). Specific irregularities in these parameters can indicate the presence of a disease, according to the research results published in Advanced Materials this year.
SEE ALSO: Technion Scientist Invents New Wearable Health System For Detecting Disease
Though certain technologies already possess these capabilities, Haick’s devices set themselves apart through self-sustainability. In particular, the gadget hopes to use cutting-edge materials that heal themselves and take advantage of the body’s wasted energy. Its components harvest the energy of body heat and movement, and they use synthetics that regenerate its properties upon damage. These advances alleviate risks such as leaving a device uncharged, torn or scratched. This technology will increasingly improve the quality of life through becoming a remote nurse that constantly accompanies an individual, according to the researchers.
Due to the constant monitoring of an individual’s vitals, these sensors provide a diagnosis of diseases in early stages. This prevents diseases from progressing, which Haick cites as a motivation for his research. “The results are very encouraging,” Haick told NoCamels this summer, pointing to recent testing done on tuberculosis screening using sensors integrated into bandages. Among the standard “healthy” ranges set for the devices are 60 to 100 heartbeats and seven to eight breaths per minute.
However, the product is only in its preliminary stages. According to Haick, though the discrete devices exist, the sensor and energy units are yet to be integrated into one product. Currently, the research team awaits a patent on a breathable self-healing platform imitating skin. Although his research team waits for further results, Haick states he is already seeking investors for what he calls a “promising and prospective technology.”
The wearable health device sector has tremendous potential. Experts predict this market will reach nearly $20 billion by 2021. Not only do these technologies monitor a patient’s vitals, they also facilitate communication between patients and healthcare professionals around the clock and reduce the cost of human labor associated with constantly checking patients.
Haick’s research group is also working on other related projects. Notably, the team is developing self-repairing multipurpose health monitors that resemble tattoos imprinted on skin. This device will make use of a field-effect transistor (FET), which can modify its behavior through a varying electric field.
According to Wikipedia, drug overdoses have become the leading cause of death of Americans under 50, with two-thirds of those deaths from opioids. In 2016, the crisis decreased
The opioid epidemic or opioid crisis is the rapid increase in the use of prescription and non-prescription opioid drugs in the United States and Canada beginning in the late 1990s and continuing throughout the next two decades. The increase in opioid overdose deaths has been dramatic, and opioids are now responsible for 49,000 of the 72,000 drug overdose deaths overall in the US in 2017. The rate of prolonged opioid use is also increasing globally.
The remainder of this text was originally published by NoCamels.com
According to the FDA, Brainsway is set to develop a device for opioid use disorder therapy. The seven other companies, a majority US-based, will develop systems for pain therapy, medication dispensation, overdose detection, drug screening, and virtual reality (VR) treatments for chronic pain.
Medical devices at any stage of development were eligible for the challenge.
The opioid crisis in the US has garnered international attention for its startling statistics. According to the US National Institute on Drug Abuse, 115 Americans die every day from an opioid overdose.
More than 40 percent of all US opioid overdose deaths in 2016 involved a prescription opioid, according to the Centers for Disease Control and Prevention. Overdose rates from prescription opioids were highest among people aged 25 to 54 years, according to the report. And based on data from Substance Abuse and Mental Health Services Administration’s national survey on drug use and health, 11.1 million people aged 12 and older had misused prescription pain relievers in 2017.
The eight companies selected for the FDA innovation challenge will work closely with the agency to “accelerate the development and expedite marketing application review of innovative products, similar to what occurs under the Breakthrough Devices Program“, which helps expedite “certain medical devices that demonstrate the potential to address unmet medical needs for life-threatening or irreversibly debilitating diseases for which no approved or cleared treatment exists or that offer significant advantages over existing approved or cleared alternatives.”
The companies will enter a 90-day collaboration to develop mutual understanding of the product profile including the patient and user needs, and the important risks and benefits, and to discuss the potential regulatory pathways going forward.
“While these products will not automatically receive marketing authorization from the FDA, the device developers will receive increased interaction with CDRH experts, guidance for clinical trial development plans, and expedited review,” wrote Drs. Jeffrey Shuren and Jonathan
“We believe the greatest opportunities for medical devices to help prevent opioid use disorder are devices that could help identify people likely to become addicted, devices that manage pain as an alternative to opioids or reduce the need for opioid medications,” they wrote.
The CDRH has cleared, granted, or approved more than 200 devices related to the treatment or management of pain, including 10 with new or novel technologies…which may reduce the need to administer opioid drugs to patients suffering from either acute or chronic pain, they said.
Brainsway was founded by Abraham Zangen, Yiftach Roth, Avner Hagai
The ubiquity of
The remainder of this text was excerpted from full-length published article in NoCamels.com
For decades, Israel has been an established world leader in medical cannabis R&D, due to the pioneering work of Hebrew University of Jerusalem Professor Raphael Mechoulam. In 1964, the renown organic chemist was the first researcher to identify cannabis’ THC compound, the chemical known for causing a “high,” laying the foundation for scientific research on cannabis and its use in modern medicine.
In the years since, Israel became among the few countries with a government-sponsored medical cannabis program, and was the first in the world earlier this year to approve a vaporizer as a medical device for the use of cannabis extracts and formulations.
Though the country’s efforts to lead in other areas – like its big plans to become a top medical cannabis exporter with an estimated $1 billion in revenue per year – have stalled due to political wrangling, Israeli cannabis startups have stepped ahead with cutting-edge, smart devices and products for cannabis cultivation, consumption, measurement, and storage.
And their sights are set on the global cannabis market, expected to be worth some $32 billion by 2022.
Oren Todoros, CEO of the branding firm CannaImpact, tells NoCamels that mixing cannabis culture with IoT (the internet of things) “has the potential to lift the industry to new heights.”
“Due to this rapid shift towards smart connected devices, growers and consumers are increasingly turning to IoT technologies, essentially comprising of sensor devices, artificial intelligence (AI) and data analytics, to bring new efficiencies to the way we grow and consume cannabis,” says Todoros, whose firm works with Israeli startup Kassi Labs, which developed a smart storage hub solution for marijuana.
Yona Cymerman, a co-founder of Can Innovation Finder (CIF), a new initiative that hopes to connect North American cannabis growers with blue-and-white tech solutions, says “the licensed producers we work with are always interested in hearing about innovative designs and technologies being developed to improve the consumer experience, and have expressed a lot of interest in devices and gadgets.”
“Israeli entrepreneurs have demonstrated great creativity in developing and designing their products, adopting concepts from other industries such as the sports market, and are aware of, and investing in the aesthetics of their products, which makes them all the more attractive for investment purposes,” she tells NoCamels.
From vaporizers and inhalers to growing environments and all-in-one storage solutions, we’re taking a closer look at seven companies that developed forward-looking “smart” gadgets for a next-generation cannabis experience and data analysis.
Alpha Tau Medical, an Israeli medical technology company that developed breakthrough radiation cancer therapy, announced on Wednesday that it would be starting a series of clinical trials with leading medical centers in Italy with the aim of receiving Europe’s CE approval by next year.
Portions of this article originally appeared in NoCamels.com
Alpha Tau Medical was founded in 2016 to focus on R&D and commercialization of its breakthrough cancer treatment, Alpha DaRT (Dіffusіng Alpha-emіtters Radіatіon Therapy). The technology, initially developed in 2003 by Professors Itzhak Kelson and Yona Keisari at Tel Aviv University, delivers high-precision alpha radiation that is released when radioactive substances decay inside the tumor, killing cancer cells while sparing the surrounding healthy tissue.
Early results from an ongoing pre-clinical trial at the Rabin Medical Center in Israel and the IRST (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori) in Italy on patients with squamous cell carcinoma (SCC) tumors, showed all tumor sizes reduced and more than 70 percent of the tumors completely disappearing within a few weeks after treatment.
The startup says the technology has been tested on over 6,000 animals in a number of studies and has been found “to be effective and safe for various indications, including tumors considered to be resistant to standard radiotherapy.”
The treatment can be applied under local anesthesia in a short single session and can be combined with other modalities such as chemotherapy and immunotherapy to increase efficacy, and can even trigger anti-tumor immunity for the elimination of distant metastases, according to Alpha Tau Medical.
The upcoming clinical trials for the technology will take place at the Sapienza University of Rome, which is initiating Alpha Tau’s clinical trial protocol for SCC of the skin and oral cavity, and the IFO (Istituti Fisioterapici Ospitalieri ), which is conducting its first study of Alpha DaRT for the treatment of cutaneous and mucosal malignant neoplasia (CMN).
The company says it is also collaborating with key cancer physicians worldwide to investigate the Alpha DaRT as a treatment for additional cancers, including pancreatic, breast, and prostate.
“The participation in Alpha Tau’s SCC protocol is a great clinical and scientific opportunity. I am proud to be able to offer this revolutionary treatment in the training course of physicians specializing in Radiotherapy,” said Professor Vincenzo Tombolini, principal investigator and radiation oncologist from La Sapienza.
“With strong, well-published findings from preclinical trials in over 6,000 animals in different types of tumors, we are proud to start Alpha TAU’s first trial investigating the Alpha DaRT as a treatment for CMN,” said Dr. Laura Eibenschutz, principal investigator and medical director from IFO.
Alpha Tau Medical CEO Uzi Sofer said the development “supports our mission to perform multiple clinical studies for different indications across the globe and build local production facilities to enable optimized local manufacturing and distribution.”
“This will help us rapidly bring to market our new Alpha DaRT cancer treatment approach and save lives,” he added.
Pharmaceutical R&D has huge barriers to entry. The cost is just too expensive for ambitious startups to even consider, on average about $2.5 billion just to bring a new drug to market. And there’s also a public interest cost which is seldom discussed. Namely, the cynical fact that drugs that can’t make much money are never developed. Hopefully, both of these impediments will lessen in the near future. Once again, artificial intelligence (AI) and machine learning (ML) are at the forefront in the drive reduce the time and cost to develop new drugs. How? By letting the molecules do the talking.
The following article was originally published in NoCamels.com
The cost of developing a new pharmaceutical drug, from the research and development stage to market approval, runs at about $2.6 billion, according to a 2014 report published by the Tufts Center for the Study of Drug Development (CSDD) cited by the Scientific American. It also takes between 10 to 15 years.
Israeli scientists say they have developed a revolutionary smart method to discover and develop new drugs, based on artificial intelligence and machine learning, that will dramatically shorten preparation time and reduce costs.Dr. Kira Radinsky, a renown data scientist and a visiting professor at the Technion – Israel Institute of Technology, and Shahar Harel, a PhD student at the university’s computer science department, presented their system late last month at the KDD 2018 conference in London, an annual event on Big Data and Machine Learning that draws prominent world academics and industry leaders.
Radinsky and Harel’s system seeks to tap into the modern-day, computerized processes of screening and selecting molecules with the greatest therapeutic potential – of which there are more than stars in the galaxy, making this an enormous task.
Their working hypothesis is that drug development “vocabulary” is similar to that of a natural language.
Harel said in a university statement that the system he and Radinsky developed, founded on artificial intelligence (AI) and deep learning, “acquired this language based on hundreds of thousands of molecules.”
“We are essentially presenting here an algorithm which addresses the creative stage of drug development – the molecule discovery stage,” said Harel. “This capacity leans upon our mathematical innovation, which enables the computer to understand the chemical language and to generate new molecules based upon a prototype.”
The researchers instructed the system to propose 1000 drugs based upon old drugs and were surprised to discover that 35 of the new drugs generated by the system are existing, FDA-approved drugs developed and approved after 1950. Radinsky said in a statement that the system “is not only a means of streamlining existing methods but also entirely new drug development and scientific practice paradigms.”
“Instead of seeking out specific correlations based upon hypotheses we formulate, we allow the computer to identify these connections from within a massive sample size, without guidance. The computer is not smarter than man, but it can cope with huge amounts of data and find unexpected correlations,” she added.
Radinsky indicated that a similar computerized process is how, in another study, the scientists managed to find the unknown side effects of various drugs and drug combinations.
“This is a novel type of science which is not built upon hypotheses tested in an experiment, rather, upon data that generated the research hypothesis,” she said.
The Technion said in a statement that the breakthrough is particularly significant in light of Eroom’s Law, which asserts that the number of new drugs approved by the FDA should decline at a rate of approximately 50 percent every nine years. The term was coined in 2012 in an article published in Nature Reviews Drug Discovery and is a reverse order of Moore, the name of Gordon Moore, one of the founders of Intel. Moore observed that the number of transistors in a dense integrated circuit doubles every two years. In contrast, Eroom’s Law notes that each year, fewer and fewer drugs are marketed.
Dr. Radinksy projects that “this new development will accelerate and reduce costs of development of new and effective drugs, thereby shortening the time patients will have to wait for the drugs. In addition, this breakthrough is expected to lead to the development of drugs that would not have been generated with the conventional pharmacological paradigm.”
The system is currently being deployed for use in collaboration with pharmaceutical companies to further analyze the additional generated molecules, the scientists said.
As first reported by NoCamels.com, spinal cord injury causes permanent changes, with symptoms which will embody loss of muscle operate, strength and sensation, further as loss of different body functions supported by the spine. probabilities of complete recovery area unit slim and also the method are long and tough, even with aggressive rehabilitation and particularly if treatment isn’t immediate.
A new study revealed within the Journal of Neurotrauma in July by researchers at Tel Aviv University claims that a prompt, uncomplicated treatment is also the only, fastest thanks to traumatizing a funiculus injury and diminish symptoms love inflammation and scarring.
The study was conducted by Dr. Angela Ruban and Dr. Yona Goldshmit from TAU’s Sackler college of medication. Goldshmit is additionally associate degree adjunct analysis fellow at the Australian Regenerative medication Institute at Monash University in Melbourne.
The main plan
The main plan, Dr. Goldshmit says, is to dam the body’s natural reaction to funiculus injury, by reducing the secondary injury as before long as attainable.
“Primary mechanical injury to funiculus tissue kills a particular quantity of neural cells. however there’s secondary injury thanks to the discharge of excess glutamates, that area unit answerable for extra useful incapacity,” Dr. Goldshmit same in a very release, “This is that the role of the catalyst injection we tend to devised.”
“We accomplished that injecting the catalyst reduces those temporary high aminoalkanoic acid levels, ever-changing the balance of concentration between brain and blood,” Dr. Ruban tells NoCamels.
More on Diane Israel.
But it’s a tough state of affairs, she warns. “When you’re making an attempt to have an effect on the central system, there area unit several aspect effects as a result of it’s therefore delicate.”
The treatment was tested on research laboratory mice and over the course of 5 days, the animals showed vital recovery from the injury, consistent with the study.
“The treatment enhanced the survival of neurons at the lesion web site} and enabled nerve fiber regeneration into the injury site, that resulted in vital useful recovery compared with the untreated mice,” Ruban same within the university statement. “This indicates that drug intervention with blood salt scavengers following funiculus injury is also neuroprotective and will produce a regenerative setting.”
The key takeaway isn’t to attend to diagnose or treat it, Ruban said. “It’s the same as salicylate, which may rescue an internal organ patient from irreversible injury if taken at intervals the primary few hours of an attack. we advise administering the injection even in cases of associate degree unsure identification. There’s no aspect result to the injection, however, it’d simply mitigate secondary injury and dramatically improve the standard of a person’s life,” she additional.
“When this new treatment is obtainable to paramedics, the implications of injuries may be dramatically reduced,” she said
Goldshmit same the goal was to scale back the number of salt that’s discharged initially. If we tend to do this, she explained, “we will moderate the inflammation and scarring, thereby weakening the injury to the tissue and sanctionative neural cells to survive.
Ruban developed the blood salt scavenging approach with the late faculty member. Vivian I. Teichberg of Israel’s Chaim Azriel Weizmann Institute of Science back in 2006, dominant the degree of salt in patients with diseases as well as brain tumor and ALS.
They didn’t focus specifically on funiculus injuries initially, instead of making an attempt to treat “neurological and pathological things with a brand new approach to evaluating neurotrauma,” Dr. Ruban same of her work with Teichberg. Dealing specifically with spine trauma solely came later with this explicit study. What took therefore long? Dr. Ruban tells NoCamels that the solution is attributed to the character of a being a high-level research worker.
Our spinal treatment, the injection of the catalyst, gave the impression to be an excellent straightforward quicky for the matter, she explained, and once you return up with a simple answer as a man of science, different scientists now say it’s too obvious, it won’t work.
“It’s within the nature of a research worker to look for one thing a lot of sophisticated,” she says, “but within the finish, this easy answer was one that truly looked as if it would work.”
Our relationship with Pot (Marijuana) is changing rapidly, both legally and socially. Not only are states moving (or have moved) to legalizing marijuana, namely Colorado and Washington, with several other states legalizing for medical use only, marijuana’s key ingredients, including CBD oil, are proving their health benefits as mood stabilizers, pain medications, and now as topical medicines, including cosmetics. By that, we’re talking about CBD oils, balms, ointments, etc., (or simply Cannabis without the psychoactive ingredients found in marijuana) being used as ointments to combat skin diseases such as psoriasis, atopic dermatitis, which are some of the most chronic autoimmune skin diseases.
And Israeli researchers are leading the way in CBD as topical oil remedies as the World Health Organization moves to redesignate CBG as 100 percent safe!
What the table set, the following article, excerpted from NoCamels.com, provides the details. You can find the entire article here.
CBD is a chemical produced by the cannabis plant, is non-psychoactive, and believed to comprise anti-inflammatory, anti-bacterial, painkilling and anti-aging properties.
Kaye says current trials on CBD and topical applications in Israel – considered to be the world leader in cannabis research – have shown that the cannabis compound could help manage “psoriasis, atopic dermatitis, some of the chronic autoimmune skin diseases. Once we started to see that it is effective topically, it is very natural that CBD would go into a broad range of topicals [lotions, balms, oils].”
Indeed, an image of this recognizable green leaf has become ubiquitous on creams, lotions, toners and facemasks promising new ways to hydrate skin, clear complexions and clean pores. CBD is the new “it” additive for beauty products.
“CBD is more like a wellness product today than a pharmaceutical,” Kaye tells NoCamels. “It’s going to be the next additive in everything. Just like Omega 3. It’s going to be in everything.”
Learn more about Diane Israel.
Not all cosmetics promoting CBD – just like not all beauty products already on the market — are of equal value. So Israeli companies with the medical cannabis science behind them are entering into joint ventures with cosmetics companies already on the market.
MGC Derma, based in Slovenia, is a joint venture between MGC Pharma and industry-credentialed cosmetics manufacturer, Dr. M. Burstein.
I can’t believe this story isn’t all over mainstream media. If this reporting is accurate, and I have no reason to question its veracity, our knowledge of biochemistry has become so precise that interventions like the one discussed below can not only prevent certain cancers from developing (that otherwise would have) but could prevent other diseases, even aging. Truly phenomenal what is going on with medicine in Israel.
This article was originally published by NoCamels.com here.
Israeli Researchers Say They Can Reprogram Cancer Cells Back To Their Pre-Cancer State
By Simona Shemer, NoCamels June 05, 2018 7 Comments
Cancer cells typically acquire a common set of properties, including unlimited proliferation potential, self-sufficiency in growth signals, resistance to cell death, and an ability to activate invasion and metastasis, as described in a seminal 2000 study by American biologists and cancer researchers Douglas Hanahan and Robert Weinberg. While cancers are diverse in type and etiology, the researchers also say they all share metabolism abnormalities, regardless of cellular or tissue origin. Tumor cell metabolism is now seen as cancer’s Achilles’ heel, providing a unique therapeutic opportunity to effectively eliminate tumor cells by targeting their energy metabolism.
Now, a group of researchers from Israel’s Ben-Gurion University of the Negev (BGU) have developed a new molecule that they claim inhibits the growth of cancer cells and reprograms them to act non-cancerous. The groundbreaking treatment is based on preventing the expression of the protein VDAC1, which is highly expressed in different types of tumors and found to alter cancer hallmarks, including the rewiring of pathways for growth and survival that underlie the malignant phenotype.
See related article: Israeli firm produces drinking water from the air.
VDAC1 is a “gatekeeper” of the mitochondria, the powerhouse of the cell, and is the “key to opening and closing the door to mitochondrial metabolism,” says the head of the research team Professor Varda Shoshan-Barmatz of the Department of Life Sciences and the National Institute for Biotechnology in the Negev (NIBN), an independent research institute facilitating pre-clinical studies of biotech research located within BGU. VDAC1 is crucial for supplying the high energy demands that characterize malignant cells, the university said in a statement.
“As VDAC1 controls cell energy and metabolic homeostasis, depletion of VDAC1 in cancer cell blocks the communication between the mitochondria and the rest of the cells,” Shoshan-Barmatz tells NoCamels.
Cancer cells have a lot more VDAC1 than normal cells, she explains, so the team looked for ways to prevent their formation. The researchers developed a molecule called siRNA, which, when applied to the cells, began inhibiting their growth. When applied to mice with tumors, Shoshan-Barmatz says, it caused the tumor to shrink to about 10 percent of an untreated tumor, indicating a rewiring of the cells. The study was conducted on mouse models of three different types of cancerous tumors — those of brain cancer, lung cancer, and breast cancer.
Applying the molecule resulted in inhibiting tumor growth, eliminating cancer stem cells, and leading the cell in the residual “tumor” to differentiate into normal-like cells, Shoshan-Barmatz says. In other words, the cells would resume the behavior of pre-cancerous cells.
“These normal-like cells have different properties from the cancer cells,” she explains. “They are sensed by the immune system. The cells still have their original mutations, we don’t fix the mutational genes. We do modify the activity of these genes to be like normal cells.”
“No strategy like this has been studied. It controls cancer cells and cancer stem cells. We eliminate cancer cells that are resistant to chemotherapy, radiation, immunotherapy, which doesn’t always kill every cancer cell,” Shoshan-Barmatz said, “It’s a very promising strategy.”
She added that although the new approach was still in its early stages, the researchers were thrilled with the initial results “that demonstrate the potential of this novel molecule for cancer treatment.”
“Several of our findings are particularly noteworthy. First, VDAC1, which is overexpressed in most cancer cells compared to healthy cells, offers a potentially wide applicability for this treatment. Second, treatment with siRNA against VDAC1 inhibited growth of cancer cell but not of non-cancerous cell, pointing to a potentially safe treatment. And most significantly, siRNA treatment of several cancer types in mouse models resulted in reprogrammed cancer cell metabolisms, leading to reduced tumor growth, induced disappearance of cancer stem cells and prompted cell differentiation. Thus, we discovered a code for reprogramming cancer cells so that they lose their oncogenic features,” Shoshan-Barmatz said in a statement released by BGU.
The researchers have teamed up with BGN Technologies, the technology company of Ben-Gurion University fostering entrepreneurship and bringing tech innovation from lab to market, in order to attract investors and raise funds, as they want to bring their findings to clinical trials on humans. While they are already in talks with some companies, Dr. Ora Horovitz, senior vice president of Business Development at BGN Technologies said, “We are now seeking partners for the further development and advancement of this promising patented treatment towards the clinic in the hope that it will lead to a novel path for cancer treatment.”